May 2026 China Innovative Drug Approvals: 5 Major New Drugs Approved
China’s innovative drug industry continues to achieve major breakthroughs.
According to public information released by China’s National Medical Products Administration (NMPA), May 2026 China innovative drug approvals included 5 newly approved therapies covering insomnia, myasthenia gravis, gout, hyperuricemia, critical limb ischemia, and HER2-positive gastric cancer.
These newly approved therapies include both Class 1 innovative drugs independently developed by Chinese pharmaceutical companies and globally innovative therapies introduced by multinational pharmaceutical companies.
Together, they reflect the continuous improvement of China’s innovative drug R&D capabilities and clinical translation strength. 🐱🏍
China pharmaceutical wholesaler DengYueMed provides an overview of the May 2026 China innovative drug approvals and the clinical significance behind these important therapies.
1. Fazamorexant: A New Mechanism Therapy for Insomnia Treatment in China
Approval Date: May 21, 2026
Developer: Jiangsu Coast Pharmaceutical Co., Ltd.
Indication: Adult insomnia
Among the May 2026 China innovative drug approvals, Fazamorexant represents a new generation therapy for adult insomnia characterized by difficulty falling asleep and sleep maintenance disorders.
Long-term sleep disorders not only affect quality of life but may also increase the risk of anxiety, depression, and cardiovascular diseases.
Traditional sedative-hypnotic drugs typically induce sleep through broad suppression of the central nervous system. In contrast, Fazamorexant targets the orexin signaling pathway.
Orexin is an important neurotransmitter that regulates wakefulness and can be regarded as the brain’s “wake switch.” In some insomnia patients, this switch fails to turn off properly at night, leading to persistent wakefulness.
By blocking orexin receptors, Fazamorexant reduces wakefulness signaling and helps the brain transition naturally from an awake state to sleep, achieving a sleep pattern closer to physiological sleep.
Compared with traditional insomnia therapies, Fazamorexant offers higher targeting specificity and may reduce the risks of drug dependence and addiction.
✅ Its approval provides a new treatment option for insomnia patients and marks the arrival of a next-generation innovative insomnia therapy in China.
2. Nipocalimab Injection: A New Precision Therapy for Generalized Myasthenia Gravis
Approval Date: May 21, 2026
Developer: Johnson & Johnson
Indication: Generalized myasthenia gravis (gMG)
Nipocalimab Injection was approved in combination with standard therapy for adult and adolescent patients aged 12 years and older with anti-acetylcholine receptor (AChR) antibody-positive or anti-muscle-specific tyrosine kinase (MuSK) antibody-positive generalized myasthenia gravis.
Generalized myasthenia gravis is a rare autoimmune disease that may cause ptosis, diplopia, swallowing difficulties, respiratory impairment, and generalized muscle weakness.
Nipocalimab is a fully human neonatal Fc receptor (FcRn)-targeted monoclonal antibody with a differentiated mechanism of action.
The drug binds with high affinity to FcRn receptors, blocks the recycling of pathogenic immunoglobulin G (IgG) antibodies, and accelerates the degradation of harmful autoantibodies, thereby reducing pathogenic IgG levels at the source and precisely targeting disease mechanisms.
✅ The inclusion of Nipocalimab in the May 2026 China innovative drug approvals further expands innovative treatment options for neuroimmunological diseases in China.
3. Ruzinurad Sodium Tablets: China’s New-Generation Gout Therapy
Approval Date: May 28, 2026
Developer: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Indication: Gout with hyperuricemia
Ruzinurad Sodium Tablets are a Class 1 innovative drug independently developed by Hengrui Pharmaceuticals for patients with gout and hyperuricemia.
Gout is a chronic metabolic disease caused by abnormal uric acid metabolism. With changing dietary habits and population aging, the number of patients with hyperuricemia in China continues to rise.
As a next-generation uric acid-lowering therapy, Ruzinurad inhibits the urate transporter 1 (URAT1), reducing uric acid reabsorption and promoting uric acid excretion.
Following its approval under the May 2026 China innovative drug approvals, Ruzinurad became the first domestically developed URAT1 inhibitor approved in China.
✅ Industry experts believe the approval further strengthens China’s competitiveness in innovative metabolic disease therapies while providing gout patients with additional long-term disease management options.
4. Donaperminogene Seltoplasmid Injection: China’s First Gene Therapy for Critical Limb Ischemia
Approval Date: May 28, 2026
Developer: Beijing Northland Biotech Co., Ltd.
Indication: Limb ulcers caused by critical limb ischemia
Donaperminogene Seltoplasmid Injection became the first approved gene therapy in China for the treatment of critical limb ischemia (CLI).
The therapy is mainly intended for patients who are not suitable candidates for revascularization procedures or have poor surgical outcomes, including patients with: 👇
- Arteriosclerosis obliterans
- Thromboangiitis obliterans
- Diabetic limb ischemia
Critical limb ischemia is an advanced stage of peripheral arterial disease, often associated with chronic pain, non-healing ulcers, and a high risk of amputation.
Donaperminogene Seltoplasmid is an innovative naked plasmid gene therapy that promotes sustained expression of HGF active isoforms through local naked plasmid DNA injection. It activates the HGF/C-MET signaling pathway, promotes angiogenesis and collateral circulation formation, and improves blood supply to ischemic tissues.
✅ As one of the highlights of the May 2026 China innovative drug approvals, this therapy represents a major milestone for China’s gene therapy industry and offers new hope for patients with limited treatment options.
5. Anbenitamab Injection: A Chinese HER2 ADC Bringing New Hope for Advanced Gastric Cancer
Approval Date: May 28, 2026
Developer: Shanghai JMT-Bio Technology Co., Ltd.
Indication: HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma
Anbenitamab Injection was approved in combination with chemotherapy for patients with HER2-positive locally advanced or metastatic gastric cancer who had previously received at least one trastuzumab-containing treatment regimen.
Gastric cancer remains one of the most common malignancies in China, accounting for nearly half of newly diagnosed gastric cancer cases worldwide each year.
HER2-positive gastric cancer represents approximately 15%–20% of all gastric cancer cases, and treatment options remain limited after failure of standard anti-HER2 therapies.
Anbenitamab is an antibody-drug conjugate (ADC) that combines antibody targeting capabilities with cytotoxic agents to precisely eliminate tumor cells.
✅ Its approval under the May 2026 China innovative drug approvals highlights continued progress in precision oncology and HER2-targeted therapies in China.
Trends Revealed by the May 2026 China Innovative Drug Approvals
The May 2026 China innovative drug approvals reflect several important trends in China’s pharmaceutical innovation landscape.
1️⃣ Broader Disease Coverage for Innovative Drugs
From insomnia and myasthenia gravis to gout, critical limb ischemia, and gastric cancer, China’s innovative drug development is expanding beyond oncology into neurological diseases, metabolic disorders, vascular diseases, and rare diseases.
2️⃣ Continued Advances in Gene Therapy and ADCs
Donaperminogene Seltoplasmid represents major progress in gene therapy, while Anbenitamab demonstrates the rapid growth of ADC therapies in solid tumors.
Both technologies are becoming key directions in global innovative drug development.
3️⃣ Continuous Growth of Domestic Innovation Capabilities
Among the 5 drugs included in the May 2026 China innovative drug approvals, 4 were developed by Chinese pharmaceutical companies, reflecting the growing maturity of China’s innovative drug R&D ecosystem.
Conclusion
In May 2026, China approved 5 innovative therapies covering insomnia, generalized myasthenia gravis, gout, hyperuricemia, critical limb ischemia, and HER2-positive gastric cancer.
With increasing investment in innovative drug research, faster regulatory review processes, and growing clinical demand, China is rapidly emerging as an important global hub for pharmaceutical innovation.
For patients worldwide, this means broader access to advanced, precision-based, and personalized treatment options.
👉 As a platform specializing in international pharmaceutical supply chain services, DengYueMed closely follows developments in China innovative drugs, branded medicines, and emerging therapies, providing pharmaceutical information consultation and compliant supply chain support for overseas medical institutions, pharmacies, and patients.
FAQ about May 2026 China Innovative Drug Approvals
What are the major China innovative drug approvals in May 2026?
The major May 2026 China innovative drug approvals included therapies for insomnia, generalized myasthenia gravis, gout with hyperuricemia, critical limb ischemia, and HER2-positive gastric cancer.
What are the latest cancer drugs approved in China?
Recent China cancer drug approvals include HER2-targeted ADC therapies, immunotherapies, and targeted treatments for gastric cancer and other solid tumors. In May 2026, Anbenitamab was approved for HER2-positive advanced gastric cancer.
Why is Donaperminogene Seltoplasmid considered important?
Donaperminogene Seltoplasmid is China’s first approved gene therapy for critical limb ischemia. It promotes angiogenesis and improves blood flow in ischemic tissues, offering a new treatment option for patients at risk of ulcers or amputation.
Can international patients access innovative drugs in China?
Some innovative drugs approved in China may be accessible through hospitals, licensed pharmacies, and compliant supply platforms such as DengYueMed, depending on local regulations and clinical indications.
